Skip to main content
An official website of the United States government

Aspirin Use Associated with Increased Survival in Biliary Tract Cancer

, by DCEG Staff

Round, white medication pills

Aspirin use after biliary tract cancer (BTC) diagnosis was associated with increased patient survival, according to a study by DCEG investigators published in JAMA Oncology on October 17, 2019.

BTC is a collection of rare malignancies with very poor outcomes, with just 5-15% of patients surviving five years, and median survival of less than one year due to late-stage at diagnosis. Aspirin has anti-inflammatory properties, which may slow the growth and spread of cancer.

Sarah Jackson, Ph.D., post-doctoral fellow, and Jill Koshiol, Ph.D., Earl Stadtman Investigator, both in the Infections and Immunoepidemiology Branch, and colleagues, analyzed data from the UK Clinical Practice Research Datalink on adult patients diagnosed with BTC between 1990-2017. Aspirin use was associated with reduced risk of death across all four subtypes of BTC: gallbladder, cholangiocarcinoma, ampulla of Vater, and overlapping lesions of the biliary tract. These findings support the use of aspirin to extend overall survival of BTC patients and is aligned with current standard of care.

Jackson, SS, et al, Association Between Aspirin Use and Biliary Tract Cancer Survival. JAMA Oncology. Oct 17, 2019. DOI:10.1001/jamaoncol.2019.4328. [Epub before print]

< Older Post

New Reports Highlight the Critical Role of Physical Activity for Cancer Prevention, Treatment, and Survival

Newer Post >

Cook Awarded Scientific Tenure by the NIH

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Aspirin Use Associated with Increased Survival in Biliary Tract Cancer was originally published by the National Cancer Institute.”